FGF19 and hepatocellular carcinoma: The non-tumorigenicity of the novel FGF19-M52 variant and its concomitant ability to maintain CYP7A1 repression, prompt us to explore its metabolic and antitumoral ability in aged Abcb4−/− mice, a murine model of impaired BA homeostasis-induced HCC.